Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy

Acta Pharm Sin B. 2018 Jul;8(4):511-517. doi: 10.1016/j.apsb.2018.05.007. Epub 2018 May 22.

Abstract

Protein kinases and phosphatases signal by phosphorylation and dephosphorylation to precisely control the activities of their individual and common substrates for a coordinated cellular outcome. In many situations, a kinase/phosphatase complex signals dynamically in time and space through their reciprocal regulations and their cooperative actions on a substrate. This complex may be essential for malignant transformation and progression and can therefore be considered as a target for therapeutic intervention. p38γ is a unique MAPK family member that contains a PDZ motif at its C-terminus and interacts with a PDZ domain-containing protein tyrosine phosphatase PTPH1. This PDZ-coupled binding is required for both PTPH1 dephosphorylation and inactivation of p38γ and for p38γ phosphorylation and activation of PTPH1. Moreover, the p38γ/PTPH1 complex can further regulate their substrates phosphorylation and dephosphorylation, which impacts Ras transformation, malignant growth and progression, and therapeutic response. This review will use the p38γ/PTPH1 signaling network as an example to discuss the potential of targeting the kinase/phosphatase signaling complex for development of novel targeted cancer therapy.

Keywords: Cancer development and progression; Kinase/phosphatase signaling network; PDZ-coupled protein-protein complex; Phosphorylation and dephosphorylation; Targeted cancer therapy.

Publication types

  • Review